Last reviewed · How we verify
ATI-1777
ATI-1777 is a small molecule inhibitor of the JAK1 and JAK2 enzymes.
ATI-1777 is a small molecule inhibitor of the JAK1 and JAK2 enzymes. Used for Moderate to severe atopic dermatitis.
At a glance
| Generic name | ATI-1777 |
|---|---|
| Sponsor | Aclaris Therapeutics, Inc. |
| Drug class | JAK inhibitor |
| Target | JAK1, JAK2 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting these enzymes, ATI-1777 reduces the activity of various cytokines and chemokines involved in inflammation and immune responses. This mechanism is thought to be beneficial in treating conditions characterized by excessive immune activity.
Approved indications
- Moderate to severe atopic dermatitis
Common side effects
- headache
- nausea
- fatigue
Key clinical trials
- Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis (PHASE2)
- Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |